Skip to main content

Precision Medicine’s Promise and Progress

As gene-based therapies move from lab to clinic, how can business and government bridge the gap between availability and access?

This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American



On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


In a co-branded Scientific American-World Economic Forum session at the Annual Meeting of New Champions, or “Summer Davos,” in Tianjin, China, Editor in Chief Mariette DiChristina leads a discussion with Aura Biosciences CEO Elisabeth de los Pinos Pont, Illumina Executive Chairman Jay Flatley and BGI President Wang Jian on how business and government can bridge the gap between availability and access as genomic technologies move from lab to clinic.